News | July 02, 2007

New Survey Analyzes Advances of Molecular Imaging Agents

July 3, 2007 – According to a new survey conducted by Applied Data Research has discovered that a new class of imaging agents can associate with highly specific markers on the surface of cells to provide unparalleled specificity, creating new opportunities for visualization, targeted drug delivery and mapping physiological changes over time.

The potential for molecular imaging is significant, but a number of challenging opportunities lay on the horizon for this promising technology. Unlike many other sectors of the healthcare industry where technology successes periodical occur that seem to propel the market forward, these opportunities are being driven by the migratory advances of academic, public (government) and commercial research programs. The few successful molecular imaging agents currently available have evolved from the research domain. The molecular imaging agent 18FDG was originally developed for research studies of glucose metabolism in the brain and heart muscle, and is now available in the U.S. and Europe for cancer imaging. SPECT and PET tracers have been developed to measure oxidative metabolism, fatty acid and amino acid metabolism, and pre- and post-synaptic receptor densities. The ability of these first-generation agents to improve diagnostic and treatment capabilities is now driving a directed effort to develop the next-generation of molecular agents.

These developments are examined in a new and comprehensive report - Molecular Imaging Agents: Evolving Capabilities, Emerging Opportunities. The report has been carefully researched and written to provide timely and insightful analysis of key factors and developments shaping this dynamic segment of the healthcare sector.

For more information: www.applieddata.org

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
News | Contrast Media | September 12, 2017
The U.S. Food and Drug Administration’s (FDA) Medical Imaging Drugs Advisory Committee (MIDAC) voted overwhelmingly...
Overlay Init